Sandoz Doesn’t Need Biosimilars Purchases, Chief Tells Finanz

Novartis AG (NOVN)’s Sandoz unit doesn’t need acquisitions in the biosimilars business, Finanz und Wirtschaft reported, citing an interview with Jeff George, who heads the unit.

George said he expects a “shakeout” in the market as some smaller companies lack the technological abilities and commercial understanding needed to bring about sophisticated biosimilars, the newspaper reported.

To contact the reporter on this story: Elena Logutenkova in Zurich at

To contact the editor responsible for this story: Frank Connelly at

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.